Loncastuximab tesirine is an antibody-drug conjugate used for the treatment of relapsed and refractory B-cell lymphomas.
Relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL) is a therapeutic challenge for patients who have undergone prior systemic therapies with limited success.[rx] Prognosis is poor and more effective therapies are needed to treat relapsed/refractory cases and improve survival. On April 23, 2021, the Food and Drug Administration granted accelerated approval for the antibody-drug conjugate, loncastuximab tesirine-lpyl, also known as Zynlonta. This therapy was developed by ADC Therapeutics and its accelerated approval for relapsed or refractory B-cell lymphoma is based on promising results from the LOTIS-2 clinical trial.[rx,rx]
Mechanism of action
Human CD19 antigen is a membrane glycoprotein in the immunoglobulin superfamily expressed in the various stages of B-cell development; it is detected in most malignancies of B-cell origin. Additionally, CD19 has rapid internalization kinetics and does not shed into the general circulation, rendering it a useful therapeutic target for antibody-drug conjugates (ADCs) in the treatment of B-cell malignancies.[rx]
Loncastuximab tesirine is an antibody-drug conjugate designed to target human CD19. It is a humanized monoclonal antibody and conjugated to SG3199, a pyrrolobenzodiazepine (PBD) dimer cytotoxin by a protease enzyme cleavable valine-alanine linker.[rx] The monoclonal IgG1 kappa antibody component binds to CD19, a transmembrane protein located on B-cell surfaces. The small molecule component, SG3199, functions as a PBD dimer and alkylating agent. Following binding to CD19, loncastuximab tesirine becomes internalized into the cell and subsequently proteolytic cleavage releases the SG3199 component. SG3199 binds to the DNA minor groove, forming cytotoxic DNA interstrand crosslinks, leading to B-cell cell death.[rx]
Loncastuximab tesirine exhibits antitumour activity against malignant B-cells, treating lymphomas. Higher exposure in Cycle 1 of therapy in clinical trials was associated with an increased incidence of Grade ≥2 adverse reactions, including liver function test abnormalities, skin and nail reactions, and liver function test abnormalities.[rx]
Indications
- Loncastuximab tesirine is indicated for the treatment of adults with relapsed or refractory large B-cell lymphoma who have undergone two or more prior lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma. The above indication is approved under accelerated FDA approval following the results of clinical studies. Continued approval is dependent upon the results of confirmatory clinical trials.[rx]
- Refractory Large B-cell Lymphoma
- Relapsed Diffuse Large B-cell Lymphoma (DLBCL)
- Loncastuximab tesirine is indicated for the treatment of adults with relapsed or refractory large B-cell lymphoma and high-grade B-cell lymphoma.
- For the treatment of adult patients with relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma
Use in Cancer
Loncastuximab tesirine-lpyl is approved to treat:
- B-cell non-Hodgkin lymphoma (NHL), including the following types:
- Diffuse large B-cell lymphoma (DLBCL).
- DLBCL in patients who had low-grade lymphoma.
- High-grade B-cell lymphoma.
It is used in adults whose cancer has relapsed (come back) or has not gotten better after at least two types of systemic therapy.
Loncastuximab tesirine-lpyl is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that it provides a clinical benefit in these patients.
Loncastuximab tesirine-lpyl is also being studied in the treatment of other types of cancer.
Contraindications
- a bad infection
- anemia
- decreased blood platelets
- low levels of a type of white blood cell called neutrophils
- pregnancy
- a patient who is producing milk and breastfeeding
- Child-Pugh class A liver impairment
Dosage
Strengths: lpyl 10 mg
Lymphoma
- 0.15 mg/kg IV over 30 minutes on Day 1 of each cycle (every 3 weeks) for 2 cycles, then 0.075 mg/kg IV over 30 minutes every 3 weeks for subsequent cycles
- Premedicate with dexamethasone 4 mg orally or IV 2 times a day for 3 days beginning the day before this drug.
- If dexamethasone administration does not begin the day before this drug, dexamethasone should begin at least 2 hours prior to administration of this drug.
Dose Adjustments
DOSE DELAYS OR MODIFICATIONS: HEMATOLOGIC ADVERSE REACTIONS:
- Neutropenia (absolute neutrophil count less than 1 x 10(9)/L): Withhold this drug until neutrophil counts return to 1 x 10(9)/L or higher.
- Thrombocytopenia (platelet count less than 50,000/mcL): Withhold this drug until platelet count returns to 50,000/mcL or higher.
NONHEMATOLOGIC ADVERSE REACTIONS:
Edema or Effusion:
- Grade 2 or higher: Withhold this drug until the toxicity resolves to Grade 1 or less.
Other Adverse Reactions:
- Grade 3 or higher: Withhold this drug until the toxicity resolved to Grade 1 or less.
- If dosing is delayed by more than 3 weeks due to toxicity related to this drug, reduce subsequent doses by 50%; if toxicity reoccurs following dose reduction, consider discontinuation.
NOTE: If toxicity requires dose reduction following the second dose of 0.15 mg/kg (Cycle 2), the patient should receive the dose of 0.075 mg/kg for Cycle 3.
Reconstitution/preparation techniques:
- Reconstitute and further dilute this drug prior to infusion.
- Use appropriate aseptic technique.
- The manufacturer product information should be consulted.
Side Effects
The Most Common
- unusual tiredness or weakness
- nausea
- diarrhea
- stomach pain
- constipation
- decreased appetite
- muscle or joint pain
- darkening of skin
- rash
- itching
- blistering or peeling skin
- swelling of the hands, feet, ankles, or lower leg
- weight gain
- swelling of the stomach area
- shortness of breath
- difficulty breathing
- chest pain
- fever, chills, headache, sore throat, ongoing cough and congestion, or other signs of infection
- warm, red, painful or swollen skin following a cut or scrape
- unusual bleeding or bruising
More common
- Black, tarry stools
- bleeding gums
- blood in the urine or stools
- body aches or pain
- chills
- cough
- ear congestion
- fever
- headache
- increased sensitivity of the skin to sunlight
- itching, skin rash
- loss of voice
- lower back or side pain
- muscle or bone pain
- pain or tenderness around the eyes and cheekbones
- painful or difficult urination
- pale skin
- pinpoint red spots on the skin
- redness or other discoloration of the skin
- severe sunburn
- sore throat
- stuffy or runny nose
- swelling of the hands, ankles, feet, or lower legs
- swelling or puffiness of the face
- tightness in the chest
- trouble breathing
- ulcers, sores, or white spots in the mouth
- unusual bleeding or bruising
- unusual tiredness or weakness
Rare
- Anxiety
- blistering, crusting, irritation, itching, or reddening of the skin
- blue or pale skin
- chest pain, possibly moving to the left arm, neck, or shoulder
- confusion
- cracked, dry, scaly skin
- darkening of the skin
- dizziness
- dry cough
- fainting
- fast heartbeat
- general feeling of discomfort or illness
- lightheadedness
- rapid, shallow breathing
- sneezing
- thickening of bronchial secretions
- Back pain
- constipation
- decreased appetite
- diarrhea
- difficulty in moving
- joint pain
- lack or loss of strength
- muscle aches, cramps, or stiffness
- nausea
- stomach pain
- swollen joints
- unusual drowsiness, dullness, or feeling of sluggishness
- vomiting
Drug Interactions
| DRUG | INTERACTION |
|---|---|
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Loncastuximab tesirine. |
| Abemaciclib | The serum concentration of Abemaciclib can be increased when it is combined with Loncastuximab tesirine. |
| Abrocitinib | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Abrocitinib. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Loncastuximab tesirine. |
| Aducanumab | The risk or severity of adverse effects can be increased when Aducanumab is combined with Loncastuximab tesirine. |
| Afatinib | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Afatinib. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Loncastuximab tesirine. |
| Alirocumab | The risk or severity of adverse effects can be increased when Alirocumab is combined with Loncastuximab tesirine. |
| Ambrisentan | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Ambrisentan. |
| Amiodarone | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Amiodarone. |
| Amivantamab | The risk or severity of adverse effects can be increased when Loncastuximab tesirine is combined with Amivantamab. |
| Anifrolumab | The risk or severity of adverse effects can be increased when Anifrolumab is combined with Loncastuximab tesirine. |
| Ansuvimab | The risk or severity of adverse effects can be increased when Loncastuximab tesirine is combined with Ansuvimab. |
| Anthrax immune | The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Loncastuximab tesirine. |
| Antilymphocyte im | The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Loncastuximab tesirine. |
| Antithymocyte imm | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Loncastuximab tesirine. |
| Apalutamide | The serum concentration of Loncastuximab tesirine can be decreased when it is combined with Apalutamide. |
| Apixaban | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Apixaban. |
| Arsenic trioxide | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Arsenic trioxide. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Loncastuximab tesirine is combined with Articaine. |
| Asciminib | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Asciminib. |
| Asfotase alfa | The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Loncastuximab tesirine. |
| Asunaprevir | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Asunaprevir. |
| Atezolizumab | The risk or severity of adverse effects can be increased when Atezolizumab is combined with Loncastuximab tesirine. |
| Atoltivimab | The risk or severity of adverse effects can be increased when Atoltivimab is combined with Loncastuximab tesirine. |
| Avanafil | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Avanafil. |
| Avatrombopag | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Avatrombopag. |
| Avelumab | The risk or severity of adverse effects can be increased when Avelumab is combined with Loncastuximab tesirine. |
| Axitinib | The serum concentration of Axitinib can be increased when it is combined with Loncastuximab tesirine. |
| Bamlanivimab | The risk or severity of adverse effects can be increased when Bamlanivimab is combined with Loncastuximab tesirine. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Loncastuximab tesirine. |
| Belantamab mafodotin | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Belantamab mafodotin. |
| Belimumab | The risk or severity of adverse effects can be increased when Belimumab is combined with Loncastuximab tesirine. |
| Belinostat | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Belinostat. |
| Belumosudil | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Belumosudil. |
| Bendamustine | The serum concentration of Bendamustine can be increased when it is combined with Loncastuximab tesirine. |
| Benralizumab | The risk or severity of adverse effects can be increased when Benralizumab is combined with Loncastuximab tesirine. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Loncastuximab tesirine is combined with Benzocaine. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Loncastuximab tesirine is combined with Benzyl alcohol. |
| Berotralstat | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Berotralstat. |
| Besilesomab | The risk or severity of adverse effects can be increased when Besilesomab is combined with Loncastuximab tesirine. |
| Betrixaban | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Betrixaban. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Loncastuximab tesirine. |
| Bezlotoxumab | The risk or severity of adverse effects can be increased when Bezlotoxumab is combined with Loncastuximab tesirine. |
| Bimekizumab | The risk or severity of adverse effects can be increased when Bimekizumab is combined with Loncastuximab tesirine. |
| Binimetinib | The serum concentration of Binimetinib can be increased when it is combined with Loncastuximab tesirine. |
| Bisoprolol | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Bisoprolol. |
| Blinatumomab | The risk or severity of adverse effects can be increased when Blinatumomab is combined with Loncastuximab tesirine. |
| Bortezomib | The serum concentration of Bortezomib can be increased when it is combined with Loncastuximab tesirine. |
| Bosutinib | The serum concentration of Bosutinib can be increased when it is combined with Loncastuximab tesirine. |
| Brentuximab ved | The serum concentration of Brentuximab vedotin can be increased when it is combined with Loncastuximab tesirine. |
| Brodalumab | The risk or severity of adverse effects can be increased when Brodalumab is combined with Loncastuximab tesirine. |
| Brolucizumab | The risk or severity of adverse effects can be increased when Brolucizumab is combined with Loncastuximab tesirine. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Loncastuximab tesirine is combined with Bupivacaine. |
| Burosumab | The risk or severity of adverse effects can be increased when Burosumab is combined with Loncastuximab tesirine. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Loncastuximab tesirine is combined with Butacaine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Loncastuximab tesirine is combined with Butamben. |
| Cabazitaxel | The serum concentration of Cabazitaxel can be increased when it is combined with Loncastuximab tesirine. |
| Cabergoline | The serum concentration of Cabergoline can be increased when it is combined with Loncastuximab tesirine. |
| Canagliflozin | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Canagliflozin. |
| Canakinumab | The risk or severity of adverse effects can be increased when Canakinumab is combined with Loncastuximab tesirine. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Loncastuximab tesirine. |
| Capmatinib | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Capmatinib. |
| Capromab pende | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Loncastuximab tesirine. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Loncastuximab tesirine is combined with Capsaicin. |
| Carfilzomib | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Carfilzomib. |
| Carvedilol | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Carvedilol. |
| Casirivimab | The risk or severity of adverse effects can be increased when Casirivimab is combined with Loncastuximab tesirine. |
| Catumaxomab | The risk or severity of adverse effects can be increased when Catumaxomab is combined with Loncastuximab tesirine. |
| Cemiplimab | The risk or severity of adverse effects can be increased when Cemiplimab is combined with Loncastuximab tesirine. |
| Ceritinib | The serum concentration of Ceritinib can be increased when it is combined with Loncastuximab tesirine. |
| Certolizumab pegol | The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Loncastuximab tesirine. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Loncastuximab tesirine. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Loncastuximab tesirine is combined with Chloroprocaine. |
| Cilgavimab | The risk or severity of adverse effects can be increased when Loncastuximab tesirine is combined with Cilgavimab. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Loncastuximab tesirine is combined with Cinchocaine. |
| Clarithromycin | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Clarithromycin. |
| Clobazam | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Clobazam. |
| Clofazimine | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Clofazimine. |
| Clomifene | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Clomifene. |
| Cobicistat | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Cobicistat. |
| Cobimetinib | The serum concentration of Cobimetinib can be increased when it is combined with Loncastuximab tesirine. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Loncastuximab tesirine is combined with Cocaine. |
| Colchicine | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Colchicine. |
| Conivaptan | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Conivaptan. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Loncastuximab tesirine. |
| Copanlisib | The serum concentration of Copanlisib can be increased when it is combined with Loncastuximab tesirine. |
| Crizotinib | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Crizotinib. |
| Curcumin | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Curcumin. |
| Cyclosporine | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Cyclosporine. |
| Dabigatran etexi | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Dabigatran etexilate. |
| Dabrafenib | The serum concentration of Dabrafenib can be increased when it is combined with Loncastuximab tesirine. |
| Daclatasvir | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Daclatasvir. |
| Dacomitinib | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Dacomitinib. |
| Dactinomycin | The serum concentration of Dactinomycin can be increased when it is combined with Loncastuximab tesirine. |
| Daptomycin | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Daptomycin. |
| Daratumumab | The risk or severity of adverse effects can be increased when Daratumumab is combined with Loncastuximab tesirine. |
| Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Loncastuximab tesirine. |
| Darolutamide | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Darolutamide. |
| Darunavir | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Darunavir. |
| Dasabuvir | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Dasabuvir. |
| Dasatinib | The serum concentration of Dasatinib can be increased when it is combined with Loncastuximab tesirine. |
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Loncastuximab tesirine. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Loncastuximab tesirine. |
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Loncastuximab tesirine. |
| Digitoxin | The serum concentration of Digitoxin can be increased when it is combined with Loncastuximab tesirine. |
| Digoxin | The serum concentration of Digoxin can be increased when it is combined with Loncastuximab tesirine. |
| Digoxin Immune | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Loncastuximab tesirine. |
| Dinutuximab | The risk or severity of adverse effects can be increased when Dinutuximab is combined with Loncastuximab tesirine. |
| Diosmin | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Diosmin. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Loncastuximab tesirine is combined with Diphenhydramine. |
| Dolutegravir | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Dolutegravir. |
| Dostarlimab | The risk or severity of adverse effects can be increased when Dostarlimab is combined with Loncastuximab tesirine. |
| Dronedarone | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Dronedarone. |
| Dulaglutide | The risk or severity of adverse effects can be increased when Dulaglutide is combined with Loncastuximab tesirine. |
| Dupilumab | The risk or severity of adverse effects can be increased when Dupilumab is combined with Loncastuximab tesirine. |
| Durvalumab | The risk or severity of adverse effects can be increased when Durvalumab is combined with Loncastuximab tesirine. |
| Duvelisib | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Duvelisib. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Loncastuximab tesirine is combined with Dyclonine. |
| Ebola Zaire va | The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Loncastuximab tesirine. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Loncastuximab tesirine. |
| Edoxaban | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Edoxaban. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Loncastuximab tesirine. |
| Eflapegrastim | The risk or severity of adverse effects can be increased when Eflapegrastim is combined with Loncastuximab tesirine. |
| Eftrenonacog a | The risk or severity of adverse effects can be increased when Eftrenonacog alfa is combined with Loncastuximab tesirine. |
| Elacestrant | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Elacestrant. |
| Elagolix | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Elagolix. |
| Elbasvir | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Elbasvir. |
| Eliglustat | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Eliglustat. |
| Elotuzumab | The risk or severity of adverse effects can be increased when Elotuzumab is combined with Loncastuximab tesirine. |
| Emapalumab | The risk or severity of adverse effects can be increased when Emapalumab is combined with Loncastuximab tesirine. |
| Emicizumab | The risk or severity of adverse effects can be increased when Emicizumab is combined with Loncastuximab tesirine. |
| Enasidenib | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Enasidenib. |
| Enfortumab ved | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Enfortumab vedotin. |
| Entrectinib | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Entrectinib. |
| Eptinezumab | The risk or severity of adverse effects can be increased when Eptinezumab is combined with Loncastuximab tesirine. |
| Erdafitinib | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Erdafitinib. |
| Erenumab | The risk or severity of adverse effects can be increased when Erenumab is combined with Loncastuximab tesirine. |
| Ertugliflozin | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Ertugliflozin. |
| Erythromycin | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Erythromycin. |
| Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Loncastuximab tesirine. |
| Esterified estrogen | Esterified estrogens may increase the thrombogenic activities of Loncastuximab tesirine. |
| Estetrol | Estetrol may increase the thrombogenic activities of Loncastuximab tesirine. |
| Estradiol | Estradiol may increase the thrombogenic activities of Loncastuximab tesirine. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Loncastuximab tesirine. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Loncastuximab tesirine. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Loncastuximab tesirine. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Loncastuximab tesirine. |
| Estriol | Estriol may increase the thrombogenic activities of Loncastuximab tesirine. |
| Estrone | Estrone may increase the thrombogenic activities of Loncastuximab tesirine. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Loncastuximab tesirine. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Loncastuximab tesirine. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Loncastuximab tesirine is combined with Ethyl chloride. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Loncastuximab tesirine is combined with Etidocaine. |
| Etoposide | The serum concentration of Etoposide can be increased when it is combined with Loncastuximab tesirine. |
| Everolimus | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Everolimus. |
| Evolocumab | The risk or severity of adverse effects can be increased when Evolocumab is combined with Loncastuximab tesirine. |
| Fanolesomab | The risk or severity of adverse effects can be increased when Fanolesomab is combined with Loncastuximab tesirine. |
| Favipiravir | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Favipiravir. |
| Fedratinib | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Fedratinib. |
| Fexofenadine | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Fexofenadine. |
| Flibanserin | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Flibanserin. |
| Fluconazole | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Fluconazole. |
| Fostemsavir | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Fostemsavir. |
| Fremanezumab | The risk or severity of adverse effects can be increased when Fremanezumab is combined with Loncastuximab tesirine. |
| Futibatinib | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Futibatinib. |
| Galcanezumab | The risk or severity of adverse effects can be increased when Galcanezumab is combined with Loncastuximab tesirine. |
| Gemcitabine | The serum concentration of Gemcitabine can be increased when it is combined with Loncastuximab tesirine. |
| Gemtuzumab o | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Loncastuximab tesirine. |
| Gilteritinib | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Gilteritinib. |
| Glasdegib | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Glasdegib. |
| Glecaprevir | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Glecaprevir. |
| Golimumab | The risk or severity of adverse effects can be increased when Golimumab is combined with Loncastuximab tesirine. |
| Grazoprevir | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Grazoprevir. |
| Guselkumab | The risk or severity of adverse effects can be increased when Guselkumab is combined with Loncastuximab tesirine. |
| Hepatitis B immune | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Loncastuximab tesirine. |
| Hu cytomegalovirus | The risk or severity of adverse effects can be increased when Human cytomegalovirus immune globulin is combined with Loncastuximab tesirine. |
| Human immunoglo | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Loncastuximab tesirine. |
| Hu Rho(D) immune | The risk or severity of adverse effects can be increased when Human Rho(D) immune globulin is combined with Loncastuximab tesirine. |
| H varicella-zoster | The risk or severity of adverse effects can be increased when Human varicella-zoster immune globulin is combined with Loncastuximab tesirine. |
| Ibalizumab | The risk or severity of adverse effects can be increased when Ibalizumab is combined with Loncastuximab tesirine. |
| Ibritumomab ti | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Loncastuximab tesirine. |
| Idarucizumab | The risk or severity of adverse effects can be increased when Idarucizumab is combined with Loncastuximab tesirine. |
| Idelalisib | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Idelalisib. |
| Imdevimab | The risk or severity of adverse effects can be increased when Imdevimab is combined with Loncastuximab tesirine. |
| Imipramine | The serum concentration of Imipramine can be increased when it is combined with Loncastuximab tesirine. |
| Imlifidase | The therapeutic efficacy of Loncastuximab tesirine can be decreased when used in combination with Imlifidase. |
| Indacaterol | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Indacaterol. |
| Inebilizumab | The risk or severity of adverse effects can be increased when Inebilizumab is combined with Loncastuximab tesirine. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Loncastuximab tesirine. |
| Inotuzumab oz | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Loncastuximab tesirine. |
| Ipilimumab | The risk or severity of adverse effects can be increased when Ipilimumab is combined with Loncastuximab tesirine. |
| Isatuximab | The risk or severity of adverse effects can be increased when Isatuximab is combined with Loncastuximab tesirine. |
| Isavuconazole | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Isavuconazole. |
| Isavuconazonium | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Isavuconazonium. |
| Istradefylline | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Istradefylline. |
| Itraconazole | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Itraconazole. |
| Ivacaftor | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Ivacaftor. |
| Ixabepilone | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Ixabepilone. |
| Ixekizumab | The risk or severity of adverse effects can be increased when Ixekizumab is combined with Loncastuximab tesirine. |
| Ketoconazole | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Ketoconazole. |
| Lanadelumab | The risk or severity of adverse effects can be increased when Lanadelumab is combined with Loncastuximab tesirine. |
| Lapatinib | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Lapatinib. |
| Larotrectinib | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Larotrectinib. |
| Lasmiditan | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Lasmiditan. |
| Lecanemab | The risk or severity of adverse effects can be increased when Lecanemab is combined with Loncastuximab tesirine. |
| Ledipasvir | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Ledipasvir. |
| Lefamulin | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Lefamulin. |
| Lemborexant | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Lemborexant. |
| Lenvatinib | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Lenvatinib. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Loncastuximab tesirine is combined with Levobupivacaine. |
| Levoketoconazole | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Levoketoconazole. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Loncastuximab tesirine is combined with Lidocaine. |
| Linagliptin | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Linagliptin. |
| Lomitapide | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Lomitapide. |
| Lonafarnib | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Lonafarnib. |
| Loperamide | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Loperamide. |
| Lopinavir | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Lopinavir. |
| Loxapine | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Loxapine. |
| Lumacaftor | The serum concentration of Loncastuximab tesirine can be decreased when it is combined with Lumacaftor. |
| Lusutrombopag | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Lusutrombopag. |
| Maftivimab | The risk or severity of adverse effects can be increased when Maftivimab is combined with Loncastuximab tesirine. |
| Mannitol | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Mannitol. |
| Margetuximab | The risk or severity of adverse effects can be increased when Margetuximab is combined with Loncastuximab tesirine. |
| Maribavir | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Maribavir. |
| Mefloquine | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Mefloquine. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Loncastuximab tesirine is combined with Meloxicam. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Loncastuximab tesirine is combined with Mepivacaine. |
| Mepolizumab | The risk or severity of adverse effects can be increased when Mepolizumab is combined with Loncastuximab tesirine. |
| Mestranol | Mestranol may increase the thrombogenic activities of Loncastuximab tesirine. |
| Methoxy po | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Loncastuximab tesirine. |
| Methylene blue | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Methylene blue. |
| Mifepristone | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Mifepristone. |
| Mirabegron | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Mirabegron. |
| Mirvetuximab | The risk or severity of adverse effects can be increased when Mirvetuximab Soravtansine is combined with Loncastuximab tesirine. |
| Mitapivat | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Mitapivat. |
| Mogamulizumab | The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Loncastuximab tesirine. |
| Morphine | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Morphine. |
| Mosunetuzumab | The risk or severity of adverse effects can be increased when Mosunetuzumab is combined with Loncastuximab tesirine. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Loncastuximab tesirine. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Loncastuximab tesirine. |
| Necitumumab | The risk or severity of adverse effects can be increased when Necitumumab is combined with Loncastuximab tesirine. |
| Neratinib | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Neratinib. |
| Netupitant | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Netupitant. |
| Nilotinib | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Nilotinib. |
| Nintedanib | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Nintedanib. |
| Nivolumab | The risk or severity of adverse effects can be increased when Nivolumab is combined with Loncastuximab tesirine. |
| Norgestimate | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Norgestimate. |
| Nortriptyline | The serum concentration of Nortriptyline can be increased when it is combined with Loncastuximab tesirine. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Loncastuximab tesirine. |
| Obinutuzumab | The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Loncastuximab tesirine. |
| Ocrelizumab | The risk or severity of adverse effects can be increased when Ocrelizumab is combined with Loncastuximab tesirine. |
| Odesivimab | The risk or severity of adverse effects can be increased when Odesivimab is combined with Loncastuximab tesirine. |
| Ofatumumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Loncastuximab tesirine. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Loncastuximab tesirine. |
| Omadacycline | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Omadacycline. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Loncastuximab tesirine. |
| Ombitasvir | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Ombitasvir. |
| Osimertinib | The serum concentration of Osimertinib can be increased when it is combined with Loncastuximab tesirine. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Loncastuximab tesirine is combined with Oxetacaine. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Loncastuximab tesirine is combined with Oxybuprocaine. |
| Pacritinib | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Pacritinib. |
| Palbociclib | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Palbociclib. |
| Paliperidone | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Paliperidone. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Loncastuximab tesirine. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Loncastuximab tesirine. |
| Panobinostat | The serum concentration of Panobinostat can be increased when it is combined with Loncastuximab tesirine. |
| Paritaprevir | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Paritaprevir. |
| Pazopanib | The serum concentration of Pazopanib can be increased when it is combined with Loncastuximab tesirine. |
| Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with Loncastuximab tesirine. |
| Pembrolizumab | The risk or severity of adverse effects can be increased when Pembrolizumab is combined with Loncastuximab tesirine. |
| Pertuzumab | The risk or severity of adverse effects can be increased when Pertuzumab is combined with Loncastuximab tesirine. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Loncastuximab tesirine is combined with Phenol. |
| Pibrentasvir | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Pibrentasvir. |
| Pirtobrutinib | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Pirtobrutinib. |
| Pitolisant | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Pitolisant. |
| Polatuzumab ved | The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Loncastuximab tesirine. |
| Polyestradiol pho | Polyestradiol phosphate may increase the thrombogenic activities of Loncastuximab tesirine. |
| Pomalidomide | The serum concentration of Pomalidomide can be increased when it is combined with Loncastuximab tesirine. |
| Ponatinib | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Ponatinib. |
| Posaconazole | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Posaconazole. |
| Pralsetinib | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Pralsetinib. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Loncastuximab tesirine is combined with Pramocaine. |
| Pravastatin | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Pravastatin. |
| Prednisolone pho | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Prednisolone phosphate. |
| Pretomanid | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Pretomanid. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Loncastuximab tesirine is combined with Prilocaine. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Loncastuximab tesirine is combined with Procaine. |
| Propafenone | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Propafenone. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Loncastuximab tesirine is combined with Proparacaine. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Loncastuximab tesirine is combined with Propoxycaine. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Loncastuximab tesirine. |
| Quinidine | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Quinidine. |
| Quinine | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Quinine. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Loncastuximab tesirine. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Loncastuximab tesirine. |
| Ranolazine | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Ranolazine. |
| Ravulizumab | The risk or severity of adverse effects can be increased when Ravulizumab is combined with Loncastuximab tesirine. |
| Raxibacumab | The risk or severity of adverse effects can be increased when Raxibacumab is combined with Loncastuximab tesirine. |
| Regorafenib | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Regorafenib. |
| Relugolix | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Relugolix. |
| Reserpine | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Reserpine. |
| Reslizumab | The risk or severity of adverse effects can be increased when Reslizumab is combined with Loncastuximab tesirine. |
| Revefenacin | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Revefenacin. |
| Rifamycin | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Rifamycin. |
| Rimegepant | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Rimegepant. |
| Riociguat | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Riociguat. |
| Ripretinib | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Ripretinib. |
| Risankizumab | The risk or severity of adverse effects can be increased when Risankizumab is combined with Loncastuximab tesirine. |
| Ritonavir | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Ritonavir. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Loncastuximab tesirine. |
| Rivaroxaban | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Rivaroxaban. |
| Rolapitant | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Rolapitant. |
| Romidepsin | The serum concentration of Romidepsin can be increased when it is combined with Loncastuximab tesirine. |
| Romosozumab | The risk or severity of adverse effects can be increased when Romosozumab is combined with Loncastuximab tesirine. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Loncastuximab tesirine is combined with Ropivacaine. |
| Sacituzumab go | The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Loncastuximab tesirine. |
| Sapropterin | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Sapropterin. |
| Saquinavir | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Saquinavir. |
| Sarecycline | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Sarecycline. |
| Sarilumab | The risk or severity of adverse effects can be increased when Sarilumab is combined with Loncastuximab tesirine. |
| Secukinumab | The risk or severity of adverse effects can be increased when Secukinumab is combined with Loncastuximab tesirine. |
| Selexipag | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Selexipag. |
| Selumetinib | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Selumetinib. |
| Sildenafil | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Sildenafil. |
| Silodosin | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Silodosin. |
| Siltuximab | The risk or severity of adverse effects can be increased when Siltuximab is combined with Loncastuximab tesirine. |
| Simeprevir | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Simeprevir. |
| Simvastatin | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Simvastatin. |
| Sirolimus | The serum concentration of Sirolimus can be increased when it is combined with Loncastuximab tesirine. |
| Sitagliptin | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Sitagliptin. |
| Sofosbuvir | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Sofosbuvir. |
| Sorafenib | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Sorafenib. |
| Sotagliflozin | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Sotagliflozin. |
| Sotorasib | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Sotorasib. |
| Sotrovimab | The risk or severity of adverse effects can be increased when Loncastuximab tesirine is combined with Sotrovimab. |
| Spesolimab | The risk or severity of adverse effects can be increased when Spesolimab is combined with Loncastuximab tesirine. |
| Stiripentol | The excretion of Loncastuximab tesirine can be decreased when combined with Stiripentol. |
| Sulesomab | The risk or severity of adverse effects can be increased when Sulesomab is combined with Loncastuximab tesirine. |
| Sutimlimab | The risk or severity of adverse effects can be increased when Sutimlimab is combined with Loncastuximab tesirine. |
| Suvorexant | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Suvorexant. |
| Sy Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Loncastuximab tesirine. |
| Sy Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Loncastuximab tesirine. |
| Tacrolimus | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Tacrolimus. |
| Tafasitamab | The risk or severity of adverse effects can be increased when Tafasitamab is combined with Loncastuximab tesirine. |
| Talazoparib | The serum concentration of Talazoparib can be increased when it is combined with Loncastuximab tesirine. |
| Tamoxifen | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Tamoxifen. |
| Tazemetostat | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Tazemetostat. |
| Technetium | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Technetium Tc-99m sestamibi. |
| Tegaserod | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Tegaserod. |
| Telaprevir | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Telaprevir. |
| Temsirolimus | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Temsirolimus. |
| Tenofovir disoproxil | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Tenofovir disoproxil. |
| Teplizumab | The risk or severity of adverse effects can be increased when Teplizumab is combined with Loncastuximab tesirine. |
| Tepotinib | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Tepotinib. |
| Tetanus immune | The risk or severity of adverse effects can be increased when Tetanus immune globulin, human is combined with Loncastuximab tesirine. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Loncastuximab tesirine is combined with Tetracaine. |
| Tezacaftor | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Tezacaftor. |
| Tezepelumab | The risk or severity of adverse effects can be increased when Tezepelumab is combined with Loncastuximab tesirine. |
| Tibolone | Tibolone may increase the thrombogenic activities of Loncastuximab tesirine. |
| Ticagrelor | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Ticagrelor. |
| Tildrakizumab | The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Loncastuximab tesirine. |
| Tipranavir | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Tipranavir. |
| Tisotumab vedotin | The risk or severity of adverse effects can be increased when Loncastuximab tesirine is combined with Tisotumab vedotin. |
| Tivozanib | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Tivozanib. |
| Tixagevimab | The risk or severity of adverse effects can be increased when Loncastuximab tesirine is combined with Tixagevimab. |
| Tocilizumab | The risk or severity of adverse effects can be increased when Tocilizumab is combined with Loncastuximab tesirine. |
| Tolvaptan | The serum concentration of Tolvaptan can be increased when it is combined with Loncastuximab tesirine. |
| Topotecan | The serum concentration of Topotecan can be increased when it is combined with Loncastuximab tesirine. |
| Toremifene | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Toremifene. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Loncastuximab tesirine. |
| Tralokinumab | The risk or severity of adverse effects can be increased when Tralokinumab is combined with Loncastuximab tesirine. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Loncastuximab tesirine. |
| Trastuzumab der | The risk or severity of adverse effects can be increased when Trastuzumab deruxtecan is combined with Loncastuximab tesirine. |
| Trastuzumab | The serum concentration of Trastuzumab emtansine can be increased when it is combined with Loncastuximab tesirine. |
| Tremelimumab | The risk or severity of adverse effects can be increased when Tremelimumab is combined with Loncastuximab tesirine. |
| Trilaciclib | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Trilaciclib. |
| Trimipramine | The serum concentration of Trimipramine can be increased when it is combined with Loncastuximab tesirine. |
| Tucatinib | Tucatinib may decrease the excretion rate of Loncastuximab tesirine which could result in a higher serum level. |
| Ublituximab | The risk or severity of adverse effects can be increased when Ublituximab is combined with Loncastuximab tesirine. |
| Ubrogepant | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Ubrogepant. |
| Umbralisib | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Umbralisib. |
| Umeclidinium | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Umeclidinium. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Loncastuximab tesirine. |
| Vandetanib | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Vandetanib. |
| Vardenafil | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Vardenafil. |
| Vedolizumab | The risk or severity of adverse effects can be increased when Vedolizumab is combined with Loncastuximab tesirine. |
| Velpatasvir | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Velpatasvir. |
| Vemurafenib | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Vemurafenib. |
| Venetoclax | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Venetoclax. |
| Verapamil | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Verapamil. |
| Vinblastine | The serum concentration of Vinblastine can be increased when it is combined with Loncastuximab tesirine. |
| Vincristine | The serum concentration of Vincristine can be increased when it is combined with Loncastuximab tesirine. |
| Vinflunine | The serum concentration of Vinflunine can be increased when it is combined with Loncastuximab tesirine. |
| Voclosporin | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Voclosporin. |
| Vorapaxar | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Vorapaxar. |
| Voxilaprevir | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Voxilaprevir. |
| Zonisamide | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Zonisamide. |
Pregnancy and Lactation
US FDA pregnancy category: Not assigned.
Pregnancy
Based on its mechanism of action, ZYNLONTA can cause embryo-fetal harm when administered to a pregnant woman, because it contains a genotoxic compound (SG3199) and affects actively dividing cells [see Clinical Pharmacology (12.1) and Nonclinical Toxicology
(13.1)]. There are no available data on the use of ZYNLONTA in pregnant women to evaluate for drug-associated risk. No animal reproduction studies were conducted with ZYNLONTA. Advise pregnant women of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other
adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
Lactation
There is no data on the presence of loncastuximab tesirine-lpyl or SG3199 in human milk, the effects on the breastfed child, or milk production. Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with ZYNLONTA and for 3 months after the last dose.
Why is this medication prescribed?
Loncastuximab tesirine-lpyl injection is used to treat a certain type of non-Hodgkin’s lymphoma (NHL; a type of cancer that begins in a type of white blood cells that normally fights infection) that did not respond to or has returned after treatment with at least two other cancer treatments. Loncastuximab tesirine-lpyl is in a class of medications called antibody-drug conjugates. It works by killing cancer cells.
How should this medicine be used?
Loncastuximab tesirine-lpyl comes as a powder to be mixed with liquid and injected into a vein over 30 minutes by a doctor or nurse in a hospital or medical facility. It is usually injected once every 3 weeks for as long as your doctor recommends that you receive treatment.
Your doctor will probably treat you with another medication before and for 2 days after each dose to help prevent certain side effects. Your doctor may need to temporarily or permanently stop your treatment or decrease your dose of loncastuximab tesirine-lpyl during your treatment. This depends on how well the medication works for you and the side effects you experience. Be sure to tell your doctor how you are feeling during your treatment with loncastuximab tesirine-lpyl.
You should know that loncastuximab tesirine-lpyl should be administered only into a vein. However, it may leak into surrounding tissue causing severe irritation or damage. Your doctor or nurse will monitor the area near where the medication was injected. If you experience any of the following symptoms, tell your doctor immediately: pain, itching, redness, swelling, or sores near the place where the medication was injected. Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient.
What special precautions should I follow?
Before receiving loncastuximab tesirine-lpyl injection,
- tell your doctor and pharmacist if you are allergic to loncastuximab tesirine-lpyl, any other medications, or any of the ingredients in loncastuximab tesirine-lpyl injection. Ask your pharmacist for a list of the ingredients.
- tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take.
- tell your doctor if you have or recently have had an infection or if you have or have ever had liver problems.
- tell your doctor if you are pregnant or plan to become pregnant, or if you plan to father a child. You or your partner should not become pregnant while you are receiving loncastuximab tesirine-lpyl. If you are female, you may need to have a pregnancy test before you start treatment, and you should use birth control to prevent pregnancy during your treatment with loncastuximab tesirine-lpyl and for 9 months after your final dose. If you are male, you and your female partner should use birth control during your treatment and continue to use birth control for 6 months after your final dose. Talk to your doctor about birth control methods that will work for you. If you or your partner become pregnant while taking loncastuximab tesirine-lpyl, call your doctor immediately. Loncastuximab tesirine-lpyl may harm the fetus.
- tell your doctor if you are breastfeeding. You should not breastfeed while you are receiving loncastuximab tesirine-lpyl and for 3 months after your final dose.
- you should know that this medication may decrease fertility in men. Talk to your doctor about the risks of receiving loncastuximab tesirine-lpyl injection.
- if you are having surgery, including dental surgery, tell the doctor or dentist that you are receiving loncastuximab tesirine-lpyl injection.
- plan to avoid unnecessary or prolonged exposure to sunlight and to wear protective clothing, sunglasses, and sunscreen. Loncastuximab tesirine-lpyl may make your skin sensitive to sunlight.
